A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given three times
weekly to patients with refractory chronic lymphocytic leukemia.